Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.